JPRN-jRCT2080220385未知2 期
Phase II clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancer
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •at least 20 years old and obtained a written informed consent
- •- Advanced breast cancer (Stage IV) or Inoperable metastatic breast cancer
- •- HER2 negative
- •- At least one measurable lesion based on RECIST criteria
- •- No previous chemotherapy for metastatic breast cancer
排除标准
- 未提供
研究者
相似试验
未知
1 期
Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220022Chugai Pharmaceutical Co., Ltd.
未知
2 期
A Phase II Trial of R435(Bevacizumab) in stage IVB, persistent or recurrent carcinoma of the cervixadvanced or recurrent carcinoma of the cervixJPRN-jRCT2080222700Chugai Pharmaceutical Co., Ltd.6
未知
3 期
A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patientschemotherapy naive and inoperable malignant pleural mesotheliomaJPRN-jRCT2080223406CHUGAI PHARMACEUTICAL CO., LTD.12
未知
3 期
A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.Gastric CancerJPRN-jRCT2080220416Chugai Pharmaceutical Co., Ltd.
未知
3 期
Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220205Chugai Pharmaceutical Co., Ltd.